Novavax is prepared to create and deliver recommended monovalent or bivalent vaccines for the fall vaccination season based on guidance from the FDA. They would like the strain recommendation to be provided by the end of Q1 (similar to influenza) to allow 6 months for vaccine manufacture, release and distribution. 21/